IFNG-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing

U. Ging Lo, Rey Chen Pong, Diane Yang, Leah Gandee, Elizabeth Hernandez, Andrew Dang, Chung Jung Lin, John Santoyo, Shihong Ma, Rajni Sonavane, Jun Huang, Shu Fen Tseng, Loredana Moro, Arnaldo A. Arbini, Payal Kapur, Ganesh Raj, Dalin He, Chih Ho Lai, Ho Lin, Jer-Tsong Hsieh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

IFNg, a potent cytokine known to modulate tumor immunity and tumoricidal effects, is highly elevated in patients with prostate cancer after radiation. In this study, we demonstrate that IFNg can induce epithelial-to-mesenchymal transition (EMT) in prostate cancer cells via the JAK–STAT signaling pathway, leading to the transcription of IFN-stimulated genes (ISG) such as IFN-induced tetratricopeptide repeat 5 (IFIT5). We unveil a new function of IFIT5 complex in degrading precursor miRNAs (pre-miRNA) that includes pre-miR-363 from the miR-106a-363 cluster as well as pre-miR-101 and pre-miR-128, who share a similar 5 0 -end structure with pre-miR-363. These suppressive miRNAs exerted a similar function by targeting EMT transcription factors in prostate cancer cells. Depletion of IFIT5 decreased IFNg-induced cell invasiveness in vitro and lung metastasis in vivo. IFIT5 was highly elevated in high-grade prostate cancer and its expression inversely correlated with these suppressive miRNAs. Altogether, this study unveils a pro-metastatic role of the IFNg pathway via a new mechanism of action, which raises concerns about its clinical application.

Original languageEnglish (US)
Pages (from-to)1098-1112
Number of pages15
JournalCancer Research
Volume79
Issue number6
DOIs
StatePublished - Jan 1 2019

Fingerprint

Epithelial-Mesenchymal Transition
MicroRNAs
Prostatic Neoplasms
Immunity
Transcription Factors
Radiation
Cytokines
Neoplasm Metastasis
Lung
Genes
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

IFNG-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing. / Lo, U. Ging; Pong, Rey Chen; Yang, Diane; Gandee, Leah; Hernandez, Elizabeth; Dang, Andrew; Lin, Chung Jung; Santoyo, John; Ma, Shihong; Sonavane, Rajni; Huang, Jun; Tseng, Shu Fen; Moro, Loredana; Arbini, Arnaldo A.; Kapur, Payal; Raj, Ganesh; He, Dalin; Lai, Chih Ho; Lin, Ho; Hsieh, Jer-Tsong.

In: Cancer Research, Vol. 79, No. 6, 01.01.2019, p. 1098-1112.

Research output: Contribution to journalArticle

Lo, UG, Pong, RC, Yang, D, Gandee, L, Hernandez, E, Dang, A, Lin, CJ, Santoyo, J, Ma, S, Sonavane, R, Huang, J, Tseng, SF, Moro, L, Arbini, AA, Kapur, P, Raj, G, He, D, Lai, CH, Lin, H & Hsieh, J-T 2019, 'IFNG-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing', Cancer Research, vol. 79, no. 6, pp. 1098-1112. https://doi.org/10.1158/0008-5472.CAN-18-2207
Lo, U. Ging ; Pong, Rey Chen ; Yang, Diane ; Gandee, Leah ; Hernandez, Elizabeth ; Dang, Andrew ; Lin, Chung Jung ; Santoyo, John ; Ma, Shihong ; Sonavane, Rajni ; Huang, Jun ; Tseng, Shu Fen ; Moro, Loredana ; Arbini, Arnaldo A. ; Kapur, Payal ; Raj, Ganesh ; He, Dalin ; Lai, Chih Ho ; Lin, Ho ; Hsieh, Jer-Tsong. / IFNG-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing. In: Cancer Research. 2019 ; Vol. 79, No. 6. pp. 1098-1112.
@article{7b8b4ed8cba1403ba2995cd8adefd474,
title = "IFNG-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing",
abstract = "IFNg, a potent cytokine known to modulate tumor immunity and tumoricidal effects, is highly elevated in patients with prostate cancer after radiation. In this study, we demonstrate that IFNg can induce epithelial-to-mesenchymal transition (EMT) in prostate cancer cells via the JAK–STAT signaling pathway, leading to the transcription of IFN-stimulated genes (ISG) such as IFN-induced tetratricopeptide repeat 5 (IFIT5). We unveil a new function of IFIT5 complex in degrading precursor miRNAs (pre-miRNA) that includes pre-miR-363 from the miR-106a-363 cluster as well as pre-miR-101 and pre-miR-128, who share a similar 5 0 -end structure with pre-miR-363. These suppressive miRNAs exerted a similar function by targeting EMT transcription factors in prostate cancer cells. Depletion of IFIT5 decreased IFNg-induced cell invasiveness in vitro and lung metastasis in vivo. IFIT5 was highly elevated in high-grade prostate cancer and its expression inversely correlated with these suppressive miRNAs. Altogether, this study unveils a pro-metastatic role of the IFNg pathway via a new mechanism of action, which raises concerns about its clinical application.",
author = "Lo, {U. Ging} and Pong, {Rey Chen} and Diane Yang and Leah Gandee and Elizabeth Hernandez and Andrew Dang and Lin, {Chung Jung} and John Santoyo and Shihong Ma and Rajni Sonavane and Jun Huang and Tseng, {Shu Fen} and Loredana Moro and Arbini, {Arnaldo A.} and Payal Kapur and Ganesh Raj and Dalin He and Lai, {Chih Ho} and Ho Lin and Jer-Tsong Hsieh",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-18-2207",
language = "English (US)",
volume = "79",
pages = "1098--1112",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - IFNG-induced IFIT5 promotes epithelial-to-mesenchymal transition in prostate cancer via miRNA processing

AU - Lo, U. Ging

AU - Pong, Rey Chen

AU - Yang, Diane

AU - Gandee, Leah

AU - Hernandez, Elizabeth

AU - Dang, Andrew

AU - Lin, Chung Jung

AU - Santoyo, John

AU - Ma, Shihong

AU - Sonavane, Rajni

AU - Huang, Jun

AU - Tseng, Shu Fen

AU - Moro, Loredana

AU - Arbini, Arnaldo A.

AU - Kapur, Payal

AU - Raj, Ganesh

AU - He, Dalin

AU - Lai, Chih Ho

AU - Lin, Ho

AU - Hsieh, Jer-Tsong

PY - 2019/1/1

Y1 - 2019/1/1

N2 - IFNg, a potent cytokine known to modulate tumor immunity and tumoricidal effects, is highly elevated in patients with prostate cancer after radiation. In this study, we demonstrate that IFNg can induce epithelial-to-mesenchymal transition (EMT) in prostate cancer cells via the JAK–STAT signaling pathway, leading to the transcription of IFN-stimulated genes (ISG) such as IFN-induced tetratricopeptide repeat 5 (IFIT5). We unveil a new function of IFIT5 complex in degrading precursor miRNAs (pre-miRNA) that includes pre-miR-363 from the miR-106a-363 cluster as well as pre-miR-101 and pre-miR-128, who share a similar 5 0 -end structure with pre-miR-363. These suppressive miRNAs exerted a similar function by targeting EMT transcription factors in prostate cancer cells. Depletion of IFIT5 decreased IFNg-induced cell invasiveness in vitro and lung metastasis in vivo. IFIT5 was highly elevated in high-grade prostate cancer and its expression inversely correlated with these suppressive miRNAs. Altogether, this study unveils a pro-metastatic role of the IFNg pathway via a new mechanism of action, which raises concerns about its clinical application.

AB - IFNg, a potent cytokine known to modulate tumor immunity and tumoricidal effects, is highly elevated in patients with prostate cancer after radiation. In this study, we demonstrate that IFNg can induce epithelial-to-mesenchymal transition (EMT) in prostate cancer cells via the JAK–STAT signaling pathway, leading to the transcription of IFN-stimulated genes (ISG) such as IFN-induced tetratricopeptide repeat 5 (IFIT5). We unveil a new function of IFIT5 complex in degrading precursor miRNAs (pre-miRNA) that includes pre-miR-363 from the miR-106a-363 cluster as well as pre-miR-101 and pre-miR-128, who share a similar 5 0 -end structure with pre-miR-363. These suppressive miRNAs exerted a similar function by targeting EMT transcription factors in prostate cancer cells. Depletion of IFIT5 decreased IFNg-induced cell invasiveness in vitro and lung metastasis in vivo. IFIT5 was highly elevated in high-grade prostate cancer and its expression inversely correlated with these suppressive miRNAs. Altogether, this study unveils a pro-metastatic role of the IFNg pathway via a new mechanism of action, which raises concerns about its clinical application.

UR - http://www.scopus.com/inward/record.url?scp=85063011974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063011974&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-2207

DO - 10.1158/0008-5472.CAN-18-2207

M3 - Article

C2 - 30504123

AN - SCOPUS:85063011974

VL - 79

SP - 1098

EP - 1112

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -